Kidney, pancreas and liver allocation and distribution in the United States

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3191-3212

  Smith, J M ^a,b   Biggins, S W ^c   Haselby, D G ^d   Kim, W R ^b,e   Wedd, J ^c   Lamb, K ^b   Thompson, B ^b   Segev, D L ^b,f   Gustafson, S ^b   Kandaswamy, R ^b,d   Stock, P G ^b,g   Matas, A J ^b,d   Samana, C J ^h   Sleeman, E F ^h   Stewart, D ^h   Harper, A ^h   Edwards, E ^h   Snyder, J J ^b,i   Kasiske, B L ^b,d   Israni, A K ^b,d,i  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e MAYO CLINIC   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNITED NETWORK FOR ORGAN SHARING   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Kidney allograft; liver allograft; organ allocation; pancreas allograft; transplant waiting list; transplantation

Indexed keywords

ARTICLE; HEALTH CARE POLICY; KIDNEY GRAFT; LIVER GRAFT; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; UNITED STATES;

HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PANCREAS TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; UNITED STATES; WAITING LISTS;

EID: 84870502855     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04259.x     Document Type: Article

References (40)

1. Organ Procurement and Transplantation Network. National waiting list data. Available at: http://optn.transplant.hrsa.gov/latestData/step2.asp. Accessed June 22, 2012.
2. Roberts JP, Wolfe RA, Bragg-Gresham JL, et al,. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545-551.
3. Ashby VB, Port FK, Wolfe RA, et al,. Transplanting kidneys without points for HLA-B matching: Consequences of the policy change. Am J Transplant 2011; 11: 1712-1718.
4. Hall EC, Massie AB, James NT, et al,. Effect of eliminating priority points for HLA-B matching on racial disparities in kidney transplant rates. Am J Kidney Dis 2011; 58: 813-816.
5. Organ Procurement and Transplantation Network. Allocation of deceased kidneys. 2011. Available at: http://optn.transplant.hrsa.gov/PoliciesandBylaws2/ policies/pdfs/policy-7.pdf. Accessed February 23, 2012.
6. Ojo AO, Hanson JA, Meier-Kriesche H, et al,. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589-597.
7. Stratta RJ, Rohr MS, Sundberg AK, et al,. Increased kidney transplantation utilizing expanded criteria deceased organ donors with results comparable to standard criteria donor transplant. Ann Surg 2004; 239: 688-697.
8. Grams ME, Womer KL, Ugarte RM, Desai NM, Montgomery RA, Segev DL,. Listing for expanded criteria donor kidneys in older adults and those with predicted benefit. Am J Transplant 2010; 10: 802-809.
9. Chapman J, Bock A, Dussol B, et al,. Follow-up after renal transplantation with organs from donors after cardiac death. Transpl Int 2006; 19: 715-719.
10. Whiting JF, Delmonico F, Morrissey P, et al,. Clinical results of an organ procurement organization effort to increase utilization of donors after cardiac death. Transplantation 2006; 81: 1368-1371.
11. Saidi RF, Elias N, Kawai T, et al,. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: Realities and costs. Am J Transplant 2007; 7: 2769-2774.
12. Colvin-Adams M, Valapour M, Hertz M, et al,. Lung and heart allocation in the United States. Am J Transplant 2012; DOI: 10.1111/j.1600-6143.2012.04258.x
13. Zachary AA, Braun WE,. Calculation of a predictive value for transplantation. Transplantation 1985; 39: 316-318.
14. Zachary AA, Steinberg AG,. Statistical analysis and applications of HLA population data. In:, Rose NR, de Marcario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology, 5th Ed., Washington, DC: ASM Press, 1997, pp. 132-140.
15. Stegall MD, Dean PG, Sung R, et al,. The rationale for the new deceased donor pancreas allocation schema. Transplantation 2007; 83: 1156-1161.
16. Organ Procurement and Transplantation Network. 3.8 Pancreas Allocation. 2010. Available at: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies. asp. Accessed December 9, 2011.
17. Freeman RB, Jr., Edwards EB,. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000; 6: 543-552.
18. Organ Procurement and Transplantation Network-HRSA. Final rule with comment period. Fed Regist 1998; 63: 16296-16338.
19. Christensen E, Schlichting P, Fauerholdt L, et al,. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-435.
20. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC,. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871.
21. Freeman RB, Jr., Wiesner RH, Harper A, et al,. The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-858.
22. Wiesner R, Edwards E, Freeman R, et al,. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
23. McDiarmid SV, Anand R, Lindblad AS,. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74: 173-181.
24. Freeman RB, Jr,. MELD/PELD: One year later. Transplant Proc 2003; 35: 2425-2427.
25. Freeman RB, Jr,. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008; 47: 1052-1057.
26. McDiarmid SV, Merion RM, Dykstra DM, Harper AM,. Selection of pediatric candidates under the PELD system. Liver Transpl 2004; 10 (Suppl 2): S23-S30.
27. HRSA/OPTN. Policy management, policies. Available at: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp. Accessed February 22, 2012.
28. Pomfret EA, Washburn K, Wald C, et al,. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
29. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
30. Yao FY, Ferrell L, Bass NM, et al,. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
31. Wiesner R, Lake JR, Freeman RB, Gish RG,. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 2006; 12 (Suppl 3): S85-S87.
32. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA,. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
33. Washburn K, Pomfret E, Roberts J,. Liver allocation and distribution: Possible next steps. Liver Transpl 2011; 17: 1005-1012.
34. Kim WR, Biggins SW, Kremers WK, et al,. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-1026.
35. Biggins SW, Kim WR, Terrault NA, et al,. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660.
36. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA,. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32-39.
37. Heuman DM, Abou-Assi SG, Habib A, et al,. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802-810.
38. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG,. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-343.
39. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS,. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008; 135: 1575-1581.
40. Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM,. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011; 140: 1952-1960.